Effect of disease severity in asthma and chronic obstructive pulmonary disease on inhaler-specific inhalation profiles through the ELLIPTA® dry powder inhaler

Journal of Aerosol Medicine and Pulmonary Drug Delivery

Volumn 28, Issue 6, 2015, Pages 486-497

  Prime, David ^a   De Backer, Wilfried ^b   Hamilton, Melanie ^a   Cahn, Anthony ^a   Preece, Andrew ^a   Kelleher, Dennis ^c   Baines, Amanda ^a   Moore, Alison ^a   Brealey, Noushin ^a   Moynihan, Jackie ^d  

^a GLAXOSMITHKLINE   (United Kingdom)

^b ANTWERP UNIVERSITY HOSPITAL   (Belgium)

^c GLAXOSMITHKLINE   (United States)

^d Synergy Clinical   (United Kingdom)

Author keywords

Asthma; COPD; Dry powder inhalers; Inhalation profile; Lung function

Indexed keywords

UMECLIDINIUM; AEROSOL; BRONCHODILATING AGENT; POWDER;

ADULT; AGED; AIRWAY RESISTANCE; ANTIBIOTIC RESISTANCE; ARTICLE; ASTHMA; BODY PLETHYSMOGRAPHY; CHRONIC OBSTRUCTIVE LUNG DISEASE; CHRONIC RESPIRATORY FAILURE; COHORT ANALYSIS; COMPARATIVE STUDY; CONE BEAM COMPUTED TOMOGRAPHY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE SEVERITY; DRUG EFFECT; DRUG SAFETY; DRY POWDER INHALER; FEMALE; FORCED EXPIRATORY VOLUME; FORCED VITAL CAPACITY; FUNCTIONAL RESIDUAL CAPACITY; HUMAN; LUNG DIFFUSION; LUNG FUNCTION TEST; MAJOR CLINICAL STUDY; MALE; MAXIMAL EXPIRATORY FLOW; MAXIMUM REACTION VELOCITY; PEAK EXPIRATORY FLOW; PEAK INSPIRATORY FLOW; RESIDUAL VOLUME; SIDE EFFECT; SPIROMETRY; TOTAL LUNG CAPACITY; TREATMENT OUTCOME; TREATMENT RESPONSE; AEROSOL; DEVICES; DRUG DELIVERY SYSTEM; EQUIPMENT DESIGN; INHALATION; INHALATIONAL DRUG ADMINISTRATION; LUNG; MIDDLE AGED; PATHOPHYSIOLOGY; POWDER; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; RANDOMIZED CONTROLLED TRIAL; SEVERITY OF ILLNESS INDEX; YOUNG ADULT;

ADMINISTRATION, INHALATION; ADULT; AEROSOLS; AGED; ASTHMA; BRONCHODILATOR AGENTS; DRUG DELIVERY SYSTEMS; DRY POWDER INHALERS; EQUIPMENT DESIGN; FEMALE; HUMANS; INHALATION; LUNG; MALE; MIDDLE AGED; POWDERS; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; SEVERITY OF ILLNESS INDEX; YOUNG ADULT;

EID: 84948763927     PISSN: 19412711     EISSN: 19412703     Source Type: Journal    
DOI: 10.1089/jamp.2015.1224     Document Type: Article

References (28)

1. Atkins PJ: Dry powder inhalers: An overview. Respir Care. 2005;50:1304-1310.
2. Berger W: Aerosol devices and asthma therapy. Curr Drug Deliv. 2009;6:38-49.
3. Ari A, and Fink JB: Guidelines for aerosol devices in infants, children and adults: Which to choose, why and how to achieve effective aerosol therapy. Expert Rev Respir Med. 2011;5:561-572.
4. Fink JB, Colice GL, and Hodder R: Inhaler devices for patients with COPD. COPD. 2013;10:523-535.
5. Ganderton D: General factors influencing drug delivery to the lung. Respir Med. 1997;91:13-16.
6. Bronsky EA, Grossman J, Henis MJ, Gallo PP, Yegen U, Della Cioppa G, Kottakis J, and Mehra S: Inspiratory flow rates and volumes with the Aerolizer dry powder inhaler in asthmatic children and adults. Curr Med Res Opin. 2004; 20:131-137.
7. Clark AR, and Hollingworth AM: The relationship between powder inhaler resistance and peak inspiratory conditions in healthy volunteers-implications for in vitro testing. J Aerosol Med. 1993;6:99-110.
8. Riley JH, Tabberer MM, Richard N, Donald AC, Church A, and Harris SS: Use of a new dry powder inhaler to deliver umeclidinium/vilanterol in the treatment of COPD. Eur Respir J. 2013;42:880s.
9. Svedsater H, Dale P, Garrill K, Walker R, and Woepse MW: Qualitative assessment of attributes and ease of use of the ELLIPTA™ dry powder inhaler for delivery of maintenance therapy for asthma and COPD. BMC Pulm Med. 2013;13:72.
10. Svedsater H, Jacques L, Goldfrad C, and Bleecker ER: Ease of use of the ELLIPTA dry powder inhaler: Data from three randomised controlled trials in patients with asthma. NPJ Prim Care Respir Med. 2014;24:14019.
11. Laube BL, Janssens HM, de Jongh FHC, Devadason SG, Dhand R, Diot P, Everard ML, Horvath I, Navalesi P, Voshaar T, and Chrystyn H: What the pulmonary specialist should know about the new inhalation therapies. ERS/ISAM Task Force report. Eur Respir J. 2011;37:1308-1331.
12. Bisgaard H, Klug B, Sumby BS, and Burnell PK: Fine particle mass from the Diskus inhaler and Turbuhaler inhaler in children with asthma. Eur Respir J. 1998;11: 1111-1115.
13. Burnell PKP, Small T, Doig S, Johal B, Jenkins R, and Gibson GJ: Ex-vivo product performance of Diskus and Turbuhaler inhalers using inhalation profiles from patients with severe chronic obstructive pulmonary disease. Respir Med. 2001;95:324-330.
14. International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use: ICH Harmonised Tripartite Guideline. Guideline for Good Clinical Practice E6(R1). Available at http://www .ich.org/fileadmin/Public-Web-Site/ICH-Products/Guidelines/ Efficacy/E6/E6-R1-Guideline.pdf. Accessed February 19, 2015.
15. World Medical Association Declaration of Helsinki: Ethical Principles for Medical Research Involving Human Subjects. Last updated 2008. Available at http://www.wma .net/en/30publications/10policies/b3/17c.pdf. Accessed February 19, 2015.
16. British Thoracic Society Scottish Intercollegiate Guidelines Network. British Guideline on the Management of Asthma. Thorax. 2008;63:iv1-iv121.
17. Global Initiative for Chronic Obstructive Lung Disease: Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. Updated December 2007. Available at http://www.goldcopd.org/Guidelines/ guidelines-global-strategy-for-diagnosis-management-2007-3 .html. Accessed February 19, 2015.
18. Global Initiative for Chronic Obstructive Lung Disease: Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. Updated January 2015. Available at http://www.goldcopd.org/guidelines-global-strategy-for-diagnosis-management.html. Accessed February 19, 2015.
19. Broeders ME, Molema J, Vermue NA, and Folgering HT: Peak inspiratory flow rate and slope of the inhalation profiles in dry powder inhalers. Eur Respir J. 2001;18:780-783.
20. Janssens JP, Pache JC, and Nicold LP: Physiological changes in respiratory function associated with ageing. Eur Respir J. 1999;13:197-205.
21. Janssens W, Vanden Brande P, Hardeman E, de Langhe E, Philps T, Troosters T, and Decramer M: Inspiratory flow rates at different levels of resistance in elderly COPD patients. Eur Respir J. 2008;3:78-83.
22. Dransfield MT, Bourbeau J, Jones PW, Hanania NA, Mahler DA, Vestbo J, Wachtel A, Martinez FJ, Barnhart F, Sanford L, Lettis S, Crim C, and Calverley PM: A once-daily inhaled corticosteroid, long-acting beta2-agonist combination, flu-ticasone furoate (FF) / vilanterol (VI), for the prevention of COPD exacerbations. Lancet Respir Med. 2013;1:210-223.
23. Martinez FJ, Boscia J, Feldman G, Scott-Wilson C, Kilbride S, Fabbri L, Crim C, and Calverley PM: Fluticasone furoate/ vilanterol (100/25; 200/25 lg) improves lung function in COPD: A randomised trial. Respir Med. 2013;107:550-559.
24. Donohue JF, Maleki-Yazdi MR, Kilbride S, Mehta R, Kalberg C, and Church A: Efficacy and safety of once-daily umeclidinium/vilanterol 62.5/25 mcg in COPD. Respir Med. 2013;107:1538-1546.
25. Celli B, Crater G, Kilbride S, Mehta R, Tabberer M, Kalberg CJ, and Church A: Once-daily umeclidinium/vilanterol 125/ 25 mcg in COPD: A randomized, controlled study. Chest. 2014;145:981-991.
26. Decramer M, Anzueto A, Kerwin E, Kaelin T, Richard N, Crater G, Tabberer M, Harris S, and Church A: Efficacy and safety of umeclidinium plus vilanterol versus tio-tropium, vilanterol, or umeclidinium monotherapies over 24 weeks in patients with chronic obstructive pulmonary disease: Results from two multicentre, blinded, randomised controlled trials. Lancet Respir Med. 2014;2:472-486.
27. Broeders MEAC, Molema J, Hop WCJ, and Folgering HTM: Inhalation profiles in asthmatics and COPD patients: Reproducibility and effect of instruction. J Aerosol Med. 2003;16:131-141.
28. Magnussen H, Watz H, Zimmermann I, Macht S, Greguletz R, Falques M, Jarreta D, and Garcia Gil E: Peak inspiratory flow through the Genuair inhaler in patients with moderate or severe COPD. Respir Med. 2009;103:1832-1837.